Photo caption: Leading brand in microbial testing, Chia-Sheng Biotech, will be listed on the Emerging Stock Market on May 28th. Chairman Tsai Yueh-ting led the management team to attend the pre-listing investor conference. (From left to right: Chia-Sheng Biotech Vice President Lin Han-yi, Chia-Sheng Biotech CFO Tsao Yu-chia, Chia-Sheng Biotech Founder Professor Tsai Wen-cheng, Chia-Sheng Biotech Chairman and General Manager Tsai Yueh-ting, Taishin Securities Chairman Kuo Chia-hung, and PwC Certified Public Accountants Chang Shu-chiung)
Today (May 26), Chia-Sheng Biotech, a leading Taiwanese brand in microbiology testing, held a pre-listing investor briefing, announcing its official listing on the Emerging Stock Market on May 28th, with the stock code 7837. Taishin Securities will serve as the sponsoring broker. Chia-Sheng Biotech Chairman and General Manager Tsai Yueh-ting stated that the company aims to become a leading international brand in the biotechnology and pharmaceutical supply chain, playing a crucial role in connecting Taiwan’s supply chain.
Chia-Sheng Biotech has maintained steady growth in recent years. Its 2024 financial report shows that its transformation strategy has yielded positive results, successfully driving continued growth in its core business. Tsai Yueh-ting also revealed that the company is actively expanding its overseas distribution channels. Partners include KSL/Pulse Scientific, a Canadian brand with over 30 years of experience selling microbiology and medical diagnostic products; UNION LAB, a South Korean distributor of microbiology testing reagents; and several Asian microbiology testing reagent distributors, such as Intuitive Technology (Hong Kong), Biomedia (Singapore), Biomed Global (Malaysia), and Genesis Lifetech (Philippines).
Kuo Chia-hung, Chairman of Taishin Securities, Tseng Kuo-tung, Chairman of WPG Holdings/YoShang Group and Chairman of MISA Chinese Business Wisdom Sharing Association, and Sheng Pao-hsi, Chairman of Po-Rei Pharmaceutical, also delivered speeches at the investor conference, emphasizing Chi-Shin’s key influence in the testing demand market such as medical services/biotechnology industry/food safety, and expressing their expectations for future expansion into the international market.
Tsai Yueh-ting stated that Chi-Sheng Biotech maintains three main development directions. First, it will continue to increase its market share in its core business, leveraging its existing biopharmaceutical supply chain to help clients launch products quickly and strengthen their competitive advantages. Second, it will develop new businesses in regenerative medicine, aiming to build a regenerative medicine industry supply chain. It plans to complete its PIC/S GMP-certified plant construction project in Zhubei this year and will collaborate with leading domestic clients. Third, it will strengthen industry cooperation, combining strategic investors to integrate upstream and downstream resources through investment or M&A strategies, continuously expanding its biopharmaceutical industry ecosystem.
Chi-Sheng Biotech has been deeply rooted in the biopharmaceutical industry for 45 years. It is a leading brand in microbiology in Taiwan, possessing the largest microbiology distribution channel in the country. It has a high coverage of domestic pharmaceutical clients and serves the upstream of the supply chain for biopharmaceutical manufacturers, third-party testing institutions, medical testing institutions, and food manufacturers. To date, the company has accumulated over 600 self-developed products, all aligned with international standards and compliant with ISO13485 and QMS (GMP) regulations. Its products follow international and domestic regulatory trends, and it continues to collaborate with academic and research institutions to develop new products, providing clients with complete product launch solutions.
Tsai Yueh-ting stated that looking ahead, Chien Hsin Biotech’s revenue is expected to maintain double-digit growth by 2025, driven by its core business and strategic investment returns. At the same time, the company will continue to strengthen industry collaborations, work with strategic investors to connect and integrate upstream and downstream resources through investment or M&A strategies, and expand the biotech and pharmaceutical industry ecosystem.
